164 related articles for article (PubMed ID: 17266536)
1. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
[TBL] [Abstract][Full Text] [Related]
2. Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.
D'Agostino B; Marrocco G; De Nardo M; Calò G; Guerrini R; Gallelli L; Advenier C; Rossi F
Br J Pharmacol; 2005 Mar; 144(6):813-20. PubMed ID: 15685213
[TBL] [Abstract][Full Text] [Related]
3. Orphanin FQ/nociceptin and [Phe(1)Psi(CH(2)-NH)Gly(2)] nociceptin(1-13)-NH(2) stimulate gastric motor function in anaesthetized rats.
Krowicki ZK; Kapusta DR; Hornby PJ
Br J Pharmacol; 2000 Aug; 130(7):1639-45. PubMed ID: 10928969
[TBL] [Abstract][Full Text] [Related]
4. The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.
Brookes ZL; Stedman EN; Brown NJ; Hebbes CP; Guerrini R; Calo G; Reilly CS; Lambert DG
PLoS One; 2013; 8(9):e74943. PubMed ID: 24086402
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.
Flau K; Redmer A; Liedtke S; Kathmann M; Schlicker E
Br J Pharmacol; 2002 Dec; 137(8):1355-61. PubMed ID: 12466246
[TBL] [Abstract][Full Text] [Related]
6. In vitro sepsis up-regulates Nociceptin/Orphanin FQ receptor expression and function on human T- but not B-cells.
Bird MF; Hebbes CP; Tamang A; Willets JM; Thompson JP; Guerrini R; Calo G; Lambert DG
Br J Pharmacol; 2023 Sep; 180(17):2298-2314. PubMed ID: 37021779
[TBL] [Abstract][Full Text] [Related]
7. Rostromedial tegmental nucleus nociceptin/orphanin FQ (N/OFQ) signaling regulates anxiety- and depression-like behaviors in alcohol withdrawn rats.
Li W; Ren Z; Tang Y; Fu Y; Sun S; Ding R; Hou J; Mai Y; Zhan B; Zhu Y; Zuo W; Ye JH; Fu R
Neuropsychopharmacology; 2023 May; 48(6):908-919. PubMed ID: 36329156
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
[TBL] [Abstract][Full Text] [Related]
9. Recovery from Traumatic Brain Injury Is Nociceptin/Orphanin FQ Peptide Receptor Genotype-, Sex-, and Injury Severity-Dependent.
Al Yacoub ON; Awwad HO; Standifer KM
J Pharmacol Exp Ther; 2024 Apr; 389(2):136-149. PubMed ID: 37442620
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological blockage of NOP receptors decreases ventral tegmental area dopamine neuronal activity through GABA
Petrella M; Borruto AM; Curti L; Domi A; Domi E; Xu L; Barbier E; Ilari A; Heilig M; Weiss F; Mannaioni G; Masi A; Ciccocioppo R
Neuropharmacology; 2024 May; 248():109866. PubMed ID: 38364970
[TBL] [Abstract][Full Text] [Related]
11. Managing Parkinson's disease: moving ON with NOP.
Mercatelli D; Bezard E; Eleopra R; Zaveri NT; Morari M
Br J Pharmacol; 2020 Jan; 177(1):28-47. PubMed ID: 31648371
[TBL] [Abstract][Full Text] [Related]
12. Central administration of Orphanin FQ inhibits GnRH secretion by ORL1 receptor in the median eminence of freely moving ovariectomized rats.
An XF; He M; Feng Y; Feng H; Yu JY
Neurosci Bull; 2009 Feb; 25(1):1-6. PubMed ID: 19190682
[TBL] [Abstract][Full Text] [Related]
13. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the distribution of spinal NOP receptors in a chronic pain model using NOP-eGFP knock-in mice.
Ozawa A; Brunori G; Cippitelli A; Toll N; Schoch J; Kieffer BL; Toll L
Br J Pharmacol; 2018 Jul; 175(13):2662-2675. PubMed ID: 29582417
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle.
Ho M; Corbett AD; McKnight AT
Br J Pharmacol; 2000 Sep; 131(2):349-55. PubMed ID: 10991930
[TBL] [Abstract][Full Text] [Related]
16. Central G-alpha subunit protein-mediated control of cardiovascular function, urine output, and vasopressin secretion in conscious Sprague-Dawley rats.
Wainford RD; Kurtz K; Kapusta DR
Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R535-42. PubMed ID: 18525017
[TBL] [Abstract][Full Text] [Related]
17. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.
Calo G; Lambert DG
Br J Anaesth; 2018 Nov; 121(5):1105-1114. PubMed ID: 30336855
[TBL] [Abstract][Full Text] [Related]
18. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Marti M; Mela F; Fantin M; Zucchini S; Brown JM; Witta J; Di Benedetto M; Buzas B; Reinscheid RK; Salvadori S; Guerrini R; Romualdi P; Candeletti S; Simonato M; Cox BM; Morari M
J Neurosci; 2005 Oct; 25(42):9591-601. PubMed ID: 16237164
[TBL] [Abstract][Full Text] [Related]
19. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
[TBL] [Abstract][Full Text] [Related]
20. Activation of NOP receptor increases vulnerability to stress: role of glucocorticoids and CRF signaling.
Holanda VAD; de Almeida RN; de Oliveira MC; da Silva Junior ED; Galvão-Coelho NL; Calo' G; Ruzza C; Gavioli EC
Psychopharmacology (Berl); 2024 May; 241(5):1001-1010. PubMed ID: 38270614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
